MedPath

Comparison of Wash Wipes and Standard Care in the Prevention of Incontinence-associated Dermatitis in Elderly

Not Applicable
Terminated
Conditions
Irritant Contact Dermatitis Due to Incontinence
Diaper Rash
Pressure Ulcer
Incontinence-associated Dermatitis
Registration Number
NCT02475512
Lead Sponsor
University Ghent
Brief Summary

Incontinence is a widespread problem in all health care setting. One of the main complications of incontinence is inflammation of the skin in the genital and anal region, also known as incontinence-associated dermatitis (IAD). IAD is a known risk factor of pressure ulcer development. Prevalence figures of IAD vary between 5.6% and 50%.

The primary aim of this study is to compare the effectiveness of a 3-in-1 genital wipe versus standard care (traditional water and soap) for the prevention of IAD. The second aim is to perform a health economic evaluation of the 3-in-1 genital wipe versus standard care, and third to compare the cost of a 2-in-1 total body wash wipe versus standard care for total body wash. Other outcomes are the comfort and tolerance of both the nurses and participants.

In this Randomized Controlled Trial, performed in 13 long-term care settings, the participants will undergo a 30 day study period. In the experimental intervention, the participants will be washed with body wash wipes and genital wipes. In the control group, the subjects will receive traditional care. IAD as well as Pressure Ulcer prevalence will be monitored. Subjective and objective time measurements will be performed.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
385
Inclusion Criteria
  • urinary incontinence, fecal incontinence or double incontinence
  • depending on help for washing
  • free of skin damage (without signs of pressure ulcers or IAD such as skin breakdown or redness)
Exclusion Criteria
  • not incontinent or minor incontinent (e.g. stress incontinence)
  • urinary or fecal catheter
  • use of incontinence wipes in the uro-genital area two weeks prior to the start of the study
  • the use of a skin barrier product in the uro-genital area two weeks prior to screening
  • presence of a bacterial/fungal infection in the uro-genital area

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Incidence and category of Incontinence-Associated Dermatitiswithin the first 30 days after start of the study
Secondary Outcome Measures
NameTimeMethod
Comfort and tolerance of the participantOn baseline, at day 14 and at day 30 (the end of the study)

Questions on comfort and tolerance of the washing method will be assessed by the caregiver. At baseline (day 0) these questions will assess the traditional care. In the middle (day 14) and at the end of the study (day 30) the comfort and tolerance of washing with wash wipes will be assessed in the experimental group. In the control group, comfort and tolerance of traditional care will be assessed three times.

Comfort and preferences of the caregiverOn baseline, at day 14 and at day 30 (the end of the study)

Questions on comfort and preferences of the washing method will be assessed. At baseline (day 0) these questions will assess the traditional care. In the middle (day 14) and at the end of the study (day 30) the comfort and preferences of washing with wash wipes will be assessed.

Cost of the experiment (use of wash wipes) versus the standard careFor the duration of the study (30 days)

* recording the daily consumption of towels, wash wipes,...

* subjective time analyses of the washing methods: Estimated time registration by the caregiver

* objective time analyses of the washing methods: time registration using a chronometer, conducted by researcher

* retrieval of overhead costs related to traditional hygienic care: washing equipment purchase costs, general water and electricity: given per institution

Incidence and category of Pressure Ulcerswithin the first 30 days after start of the study
adverse effects of the interventionwithin the first 30 days after start of the study

Adverse effects such as skin irritation, rash, itching, treatment related pain, skin dryness related to the interventions under study will be monitored.

Trial Locations

Locations (10)

Woonzorgcentrum Sint-Jozef

🇧🇪

Kortrijk, Belgium

Woonzorgcentrum Ceder aan de Leie

🇧🇪

Harelbeke, Belgium

Woonzorgcentrum Heilig Hart

🇧🇪

Kortrijk, Belgium

Woonzorgcentrum De Samaritaan

🇧🇪

Nukerke, Belgium

Woonzorgcentrum de Boarebreker

🇧🇪

Oostende, Belgium

Woonzorgcentrum De Kroon

🇧🇪

Sint-Gillis-Waas, Belgium

Woonzorgcentrum Deken Darras

🇧🇪

Tielt, Belgium

Woonzorgcentrum Onze Lieve Vrouw van Lourdes

🇧🇪

Wakken, Belgium

Woonzorgcentrum Duneroze

🇧🇪

Wenduine, Belgium

Woonzorgcentrum Sint-Camillus

🇧🇪

Wevelgem, Belgium

Woonzorgcentrum Sint-Jozef
🇧🇪Kortrijk, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.